Asad Uz Zaman

#2221301
#Secondary Research

Market for Anti-Biotics in Bangladesh

Antibiotic is a drug which is used orally or through injection to prevent any bacterial infection on
human or animal. Penicillin, which was discovered in 1928, became the first antibiotic to be mass
produced after the Second World War. Over the last decade the use of antibiotics in Bangladesh has
increased significantly.

Market Size-
According to UCB Asset Management's data, the yearly growth rate of antimicrobial drug sales was
2.3 percent, the lowest among all categories of medicines.
Antibiotic drugs accounted for Tk 2,199 crore, or 18.40% of total sales in 2015. In 2019-20, sales
totaled Tk 3,283 crore, accounting for 14% of the industry's overall revenue.

 Square pharmaceutical company (17%)

 Incepta pharmaceutical (11.6%)
 Beximco pharmaceutical (9%)
 Health care pharmaceutical (6.3%)
 Opsonin pharma (5.3%)
 Others (51%)

Growth of Demand-
According to a recent DGDA and WHO report, antibiotic usage in Bangladesh has increased by 30.81
percent in the previous two years.
According to study data, the number of persons with antibiotic resistance was just 6.5 percent in 2010,
but it grew to 14.5 percent in 2018.
Antibiotic prescriptions are most common in Bangladesh among children aged 5 to 11, as well as
those over the age of 65. Males take in 20% more antibiotics than females.

Change in price-
In developing nations such as Bangladesh, the biggest impediments to the health-care system are
rising drug prices and limited supply of medications.
Medicine costs are not much higher than worldwide benchmark prices. In compared to the WHO aim,
drug prices in Bangladesh were significantly cheaper. Medicine prices in Bangladesh were close to
the WHO objective. The necessary antibiotics were inexpensive. The statistics show that the
antibiotics addressed by the study have a wide price range. Some therapies are inexpensive to low-
income households. This is especially true for vital medicines used to treat various ailments.

1|Page
Asad Uz Zaman
#2221301
#Secondary Research

New Entrants to the market

Developing new drugs takes a significant amount of time, effort, scientific investigation, and money.
Antibiotic development for highly resistant bacterial diseases is very difficult since only a limited
percentage of people suffer these illnesses and satisfy the standards for traditional clinical trials.
Approximately 43 new antibiotics with the potential to treat dangerous bacterial infections were in
clinical development as of December 2019, with four authorized since the previous update in June
2019. 15 antibiotics were in Phase 1 clinical trials, 13 were in Phase 2, 13 were in Phase 3, and two
had new drug applications submitted. Historically, around 60% of medications that enter Phase 3 are
approved.

Consumer attitude and preferences

People accessed medicines through five numerous mediums: drug stores, private clinics,
government/charitable hospitals, community/family planning clinics, and specialized/private
hospitals. Drug stores allowed easy access to treatments for common, lack of educattion, and acute
illnesses. For chronic or serious conditions, the healthcare pathway may involve encounters with
multiple of these places, however medications sold by pharmacy stores are frequently used.
According to a study of antibiotic selling dispensers in rural areas, over 92% were private and only
8% were public. Furthermore, around 52% of them operate unofficially, that is, without any legal
authority. According to a poll, 67.3% of pharmacy sellers are unfamiliar with antibiotics. Lack of
education plays an important role for the usage of antibiotics.

2|Page
Asad Uz Zaman
#2221301
#Secondary Research

Sources:

https://www.tbsnews.net/bangladesh/health/52-icu-patients-bsmmu-multi-antibiotic-resistant
https://thefinancialexpress.com.bd/trade/pharma-industry-growth-halves-in-2020-1610159516
https://joppp.biomedcentral.com/articles/10.1186/s40545-020-00212-8
https://www.thedailystar.net/frontpage/antibiotics-use-and-sale-in-bangladesh-without-prescription-
continues-1853359
https://www.thedailystar.net/business/economy/news/anti-ulcer-drugs-sales-cross-tk-4200cr-2981651
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225270
https://www.dhakatribune.com/bangladesh/2022/05/18/antibiotics-will-require-red-colour-packaging-
from-december
https://www.dhakatribune.com/bangladesh/2022/05/18/antibiotics-will-require-red-colour-packaging-
from-december
https://biomedpharmajournal.org/vol12no4/the-study-of-availability-affordability-and-price-variation-
of-essential-antibiotics-in-bangladesh/
https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/tracking-the-global-
pipeline-of-antibiotics-in-development

3|Page